Experimental blood thinner tested in heart attack emergency

NCT ID NCT00546260

Terminated Disease control Sponsor: Alexion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an intravenous antiplatelet drug called PRT060128 in 70 people having a severe heart attack (STEMI). The goal was to see if giving the drug before emergency artery-opening treatment improved blood flow and was safe. The trial was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PRT060128 (antiplatelet drug)
What this could lead to: If successful, this could point toward a faster-acting antiplatelet option for heart attack patients undergoing emergency artery-opening procedures.
What could go wrong: This was a small, early-phase trial that was terminated, so results are limited. The drug may increase bleeding risk without clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myocardial infarction ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYOCARDIAL INFARCTION

Contacts and locations

Locations

Atlantic Health Services

Saint John, New Brunswick, E2L4L2, Canada
Centre Hospitalier Universitaire de Montreal - Hotel Dieu

Montreal, Quebec, H2W1T8, Canada
Foothills Hospital

Calgary, Alberta, T2N2T9, Canada
Geisinger Medical Center

Danville, Pennsylvania, 17822, United States
General Hospital - Heath Sciences Centre

St. John's, Newfoundland and Labrador, A1B3V6, Canada
Genesys Regional Medical Center

Grand Blanc, Michigan, 48439, United States
Hamilton Health Sciences

Hamilton, Ontario, L8L2X2, Canada
Henry Ford Hospital

Detroit, Michigan, 48202, United States
Hospital du Sacre Coeur

Montreal, Quebec, H4N1C5, Canada
Iowa Heart Center

Des Moines, Iowa, 50314, United States
Lindner Clinical Trial Center

Cincinnati, Ohio, 45219, United States
London Health Sciences

London, Ontario, N6A5A5, Canada
Maine Medical Center

Portland, Maine, 04102, United States
Montreal Heart Institute

Montreal, Quebec, H1T1C8, Canada
Queen Elizabeth II Health Sciences Centre

Halifax, Nova Scotia, B3H3A7, Canada
Regina General Hospital

Regina, Saskatchewan, S4P0W5, Canada
Royal Alexandria Hospital

Edmonton, Alberta, T5H3V7, Canada
Soutlake Regional Health Centre

Newmarket, Ontario, L3Y2R2, Canada
St. Joseph Mercy - Oakland

Pontiac, Michigan, 48341, United States
St. Paul's Hospital

Vancouver, British Columbia, V6Z1Y6, Canada
Sunnybrook Health Sciences Centre

Toronto, Ontario, M4N3M5, Canada
Tallahassee Memorial Medical Center

Tallahassee, Florida, 32308, United States
The Heart Center

Kingsport, Tennessee, 37660, United States
Trillium Health Centre - Mississaugua

Mississauga, Ontario, L5B2P7, Canada
University of Alberta Hospital

Edmonton, Alberta, T6G2B7, Canada
University of Kentucky Hospital, Gill Heart Center

Lexington, Kentucky, 40536, United States
Vancouver General Hospital

Vancouver, British Columbia, V5Z1M9, Canada
Victoria Heart Institute, Royal Jubilee Hospital

Victoria, British Columbia, V8R4R2, Canada
Washington Adventist Hospital

Takoma Park, Maryland, 20912, United States
William Beaumont Hospital

Royal Oak, Michigan, 48073, United States
William Beaumont Hospital - Troy Cardiology

Troy, Michigan, 48085, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.